Citations

Clear

24 citation(s) found for "David, William".

Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies
Dubey, Divyanshu , David, William S., Amato, Anthony A. , Reynolds, Kerry L. , Clement, Nathan F., Chute, Donald F., Mooradian, Meghan J. , Sullivan, Ryan J. , Guidon, Amanda C. , Cohen, Justine V, Lawrence, Donald P. , Dubey, Divyanshu , Cohen, Justine Vanessa

Mayo Clinic

Neurology | August 13, 2019 | Volume: 93 | Issue: 11 | Pages: No page available

10.1212/wnl.0000000000008091 | PMID 31405908 Get It

Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines
Chang, Susan M. , Messersmith, Hans , Ahluwalia, Manmeet S. , Gaspar, Laurie E., Gatson, Na Tosha , Khasraw, Mustafa , Lassman, Andrew B. , Maués, Julia , Mrugała, Maciej M. , Raizer, Jeffrey J. , Schiff, David , Stevens, Glen , Sumrall, Ashley , Bent, Martin J. van den , Vogelbaum, Michael A. , van den Bent, Martin J , Khasraw, Mustafa , Gatson, Na Tosha N , Messersmith, Hans , Sumrall, Ashley , Ahluwalia, Manmeet S , Chang, Susan Marina , Andrews, David William , Brastianos, Priscilla K. , Jordan, Justin T.

Mayo Clinic

Journal of Clinical Oncology | March 18, 2019 | Volume: 37 | Issue: 13 | Pages: 1130-1135

10.1200/jco.18.02085 | PMID 30883246 Get It

PURPOSE The Congress of Neurological Surgeons (CNS) has developed a series of guidelines for the treatment of adults with metastatic brain tumors, including systemic therapy and supportive care topics. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS Two CNS guidelines were reviewed for developmental rigor by methodologists, and an independent multidisciplinary Expert Panel was formed to review the content and assess agreement with the recommendations. The Expert Panel voted to endorse the two guidelines, and ASCO and Society for Neuro-Oncology (SNO) independently reviewed and approved the ASCO/SNO guideline endorsement. RESULTS The ASCO/SNO Expert Panel determined that the recommendations from the CNS anticonvulsants and steroids guidelines, published January 9, 2019, are clear, thorough, and based on the most relevant scientific evidence. ASCO/SNO endorsed these two CNS guidelines with minor alterations. RECOMMENDATIONS Key recommendations include the following: prophylactic antiepileptic drugs were not recommended for routine use; and corticosteroids, specifically dexamethasone, were recommended for temporary symptomatic relief in patients with neurologic symptoms and signs related to mass effect from brain metastases. Additional information is available at www.asco.org/neurooncology-guidelines .
Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials
Maurer, Matthew J. , Ghesquières, Hervé , Link, Brian K. , Jais, Jean‐Philippe, Thompson, Carrie A. , Haïoun, Corinne , Allmer, Cristine, Johnston, Patrick B. , Delarue, Richard, Micallef, Ivana N. , Peyrade, Frédéric, Inwards, David J. , Ketterer, Nicolas , Farooq, Umar , Fitoussi, Olivier , Macon, William R. , Molina, Thierry Jo , Syrbu, Sergei , Weiner, George J. , Ansell, Stephen M. , Salles, Gilles , Tilly, Hervé , Nowakowski, Grzegorz S. , Molina, Thierry J, Salles, Gilles A, Maurer, Matthew , Link, Brian K , Farooq, Umar , Salles, Gilles A , Weiner, George , Jaïs, Jean‐Philippe , Habermann, Thomas M. , Feldman, Andrew L. , Slager, Susan L. , Cerhan, James R. , Witzig, Thomas E. , Syrbu, Sergei

Mayo Clinic

Journal of Clinical Oncology | April 19, 2018 | Volume: 36 | Issue: 16 | Pages: 1603-1610

10.1200/jco.2017.76.5198 | PMID 29672223 Get It

Purpose Selection bias in clinical trials has consequences for scientific validity and applicability of study results to the general population. There is concern that patients with clinically aggressive disease may not have enrolled in recent diffuse large B-cell lymphoma (DLBCL) trials due to the consent process and the inability to delay therapy for eligibility evaluation. We have examined the diagnosis-to-treatment interval (DTI) and its association with clinical factors and outcome in a clinic-based observational cohort of patients with DLBCL from the United States. Validation of results was performed in an independent, clinical trial-based cohort from Europe. Patients and Methods Patients were prospectively enrolled in the University of Iowa and Mayo Clinic Specialized Programs of Research Excellence Molecular Epidemiology Resource (MER; N = 986) or the Lymphoma Study Association (LYSA) LNH-2003 clinical trials program (N = 1,444). All patients received anthracycline-based immunochemotherapy at initial diagnosis. Associations of DTI with clinical factors and outcome were examined. Outcome was assessed using event-free survival at 24 months from diagnosis (EFS24). Results Median (range) DTI was 15 days (0 to 155 days in the MER and 23 days (0 to 215 days) in LYSA. Shorter DTI was strongly associated with adverse clinical factors, including elevated lactate dehydrogenase levels, poor performance status, B symptoms, and higher International Prognostic Index in both cohorts (all P < .001). Longer DTI was associated with improved EFS24 in both the MER (per-week odds ratio, 0.80; 95% CI, 0.74 to .0.87) and LYSA (per-week odds ratio, 0.90; 95% CI, 0.86 to 0.94); association with EFS24 remained significant after adjustment for International Prognostic Index. Conclusion DTI is strongly associated with prognostic clinical factors and outcome in newly diagnosed DLBCL. DTI should be reported in all clinical trials of newly diagnosed DLBCL and future trials should take steps to avoid selection bias due to treatment delay.
Distinctive microbiomes and metabolites linked with weight loss after gastric bypass, but not gastric banding
Ilhan, Zehra Esra , DiBaise, John K. , Hoyt, David , Marcus, Andrew K. , Krajmalnik‐Brown, Rosa , Hoyt, David W , Isern, Nancy , Kang, Dae‐Wook , Crowell, Michael D. , Rittmann, Bruce E.

Mayo Clinic

The ISME Journal | May 26, 2017 | Volume: 11 | Issue: 9 | Pages: 2047-2058

10.1038/ismej.2017.71 | PMID 28548658 Get It

Abstract Roux-en-Y gastric bypass (RYGB) and laparoscopic adjustable gastric banding (LAGB) are anatomically different bariatric operations. RYGB achieves greater weight loss compared with LAGB. Changes in the gut microbiome have been documented after RYGB, but not LAGB, and the microbial contribution to sustainable surgical weight loss warrants further evaluation. We hypothesized that RYGB imposes greater changes on the microbiota and its metabolism than LAGB, and that the altered microbiota may contribute to greater weight loss. Using multi-omic approaches, we analyzed fecal microbial community structure and metabolites of pre-bariatric surgery morbidly obese (PreB-Ob), normal weight (NW), post-RYGB, and post-LAGB participants. RYGB microbiomes were significantly different from those from NW, LAGB and PreB-Ob. Microbiome differences between RYGB and PreB-Ob populations were mirrored in their metabolomes. Diversity was higher in RYGB compared with LAGB, possibly because of an increase in the abundance of facultative anaerobic, bile-tolerant and acid-sensible microorganisms in the former. Possibly because of lower gastric acid exposure, phylotypes from the oral cavity, such as Escherichia, Veillonella and Streptococcus, were in greater abundance in the RYGB group, and their abundances positively correlated with percent excess weight loss. Many of these post-RYGB microorganisms are capable of amino-acid fermentation. Amino-acid and carbohydrate fermentation products—isovalerate, isobutyrate, butyrate and propionate—were prevalent in RYGB participants, but not in LAGB participants. RYGB resulted in greater alteration of the gut microbiome and metabolome than LAGB, and RYGB group exhibited unique microbiome composed of many amino-acid fermenters, compared with nonsurgical controls.
RTOG 0525: Molecular correlates from a randomized phase III trial of newly diagnosed glioblastoma.
Aldape, Ken, Wang, M., Colman, Howard , Jones, G. T., Chakravarti, Arnab , Long, Lihong, Diefes, Kristin, Heathcock, Lindsey, Jenkins, Rosalind E. , Gilbert, M. R., Group, Radiation Therapy Oncology, Sulman, Erik P. , Hegi, Monika E. , Colman, Howard , Mehta, Minesh P. , Andrews, David William , Jenkins, R., Schultz, Carl Johann , Group, Radiation Therapy Oncology

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 29 | Issue: 18_suppl | Pages: LBA2000-LBA2000

10.1200/jco.2011.29.18_suppl.lba2000 Get It

LBA2000 Background: Formalin-fixed, paraffin embedded GBM tumor tissue, adequate for conventional MGMT methylation analyses, was required for entry onto the RTOG 0525 clinical trial. Methods: Four prognostic biomarkers were evaluated on a training set of 220 retrospectively obtained GBM samples, consisting of IDH1 mutation, the glioma-CpG island methylator phenotype (G-CIMP), a microarray-based mRNA panel and a novel MGMT promoter methylation assay. For each biomarker, 2 (IDH1 and mRNA) or 3 subgroups (G-CIMP and MGMT) were defined based on associations with overall survival. All combinations (36 possible) of each of the 4 biomarker-derived subgroups were then defined and compared with survival data and then consolidated into 4 risk groups. Once created in the training set, this model was applied to the RTOG 0525 samples (n=763) for external validation. Results: Application of the molecular risk classification to RTOG 0525 samples (left table) showed a highly significant survival association (p<0.001). When compared to the recursive partitioning analysis (RPA, table on right), this composite molecular classifier better identified patients with long term survival and appears to improve resolution by revealing an additional distinct risk group. The molecular classifier was prognostic in each of the treatment arms individually. Conclusions: Four distinct biomarkers or biomarker panels were tested in GBM. These biomarkers were compared with clinical outcome in a training set to optimize a method to combine them into a classifier. This classifier was then validated on a large sample set from a large phase III clinical trial. This composite panel may represent an improvement over the existing RPA with respect to risk stratification of patients for GBM. Additionally, it has the potential to impact future clinical trial designs and provide enhanced opportunities for personalization of therapy for GBM. Support: NCI U10 CA2121661, U10 CA37422, P50 CA127001. [Table: see text]
Stroke Diagnosis and Treatment in the Emergency Department
Siegel, Jason , Pizzi, Michael , Freeman, William D. , Siegel, Jason L, Pizzi, Michael A. , Freeman, William David, Freeman, William D

Mayo Clinic

JAMA Neurology | January 23, 2017 | Volume: 74 | Issue: 3 | Pages: 362

10.1001/jamaneurol.2016.5561 | PMID 28114682 Get It

Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy
Lynn, Amanda M., Singh, Siddharth , Congly, Stephen E. , Khemani, Disha, Johnson, David H., Wiesner, Russell H., Kamath, Patrick S. , Andrews, James C. , Leise, Michael D.

Mayo Clinic

Liver Transplantation | March 12, 2016 | Volume: 22 | Issue: 6 | Pages: 723-731

10.1002/lt.24440 | PMID 26970243 Get It

Treatment options for refractory hepatic encephalopathy (HE) are limited. Patients who fail medical management may harbor large portosystemic shunts (PSSs) which are possible therapeutic targets. This study aims to describe patient selection, effectiveness, and safety of percutaneous PSS embolization in those with medically refractory HE. A retrospective evaluation of consecutive adult patients with medically refractory HE referred for PSS embolization at a tertiary center was performed (2003‐2015). Patient data collected included the type of HE, medications, Model for End‐Stage Liver Disease (MELD) score, shunt type, embolization approach, and materials used. Outcomes of interest were immediate (7 days), intermediate (1‐4 months), and longer‐term (6‐12 months) effectiveness and periprocedural safety. Effectiveness was determined based on changes in hospitalization frequency, HE medications, and symptoms. Twenty‐five patients with large PSS were evaluated for shunt embolization. Five were excluded due to high MELD scores (n = 1), comorbid conditions (n = 1), or technical considerations (n = 3). Of 20 patients who underwent embolization, 13 had persistent and 7 had recurrent HE; 100% (20/20) achieved immediate improvement. Durable benefit was achieved in 100% (18/18) and 92% (11/12) at 1‐4 and 6‐12 months, respectively. The majority (67%; 8/12) were free from HE‐related hospitalizations over 1 year; 10% developed procedural complications, and all resolved. Six developed new or worsening ascites. In conclusion, PSS embolization is a safe and effective treatment strategy that should be considered for select patients with medically refractory HE. Liver Transplantation 22 723–731 2016 AASLD.
Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine
Burns, Ted M., Smith, Gordon, Allen, Jeffrey A. , Amato, Anthony A. , Arnold, W. David , Barohn, Richard J., Benatar, Michael , Bird, Shawn J. , Bromberg, Mark B. , Chahin, Nizar, Ciafaloni, Emma , Corse, Andrea M. , David, William S., Dimberg, Elliot L., Sousa, De , Donofrio, Peter D., Dyck, P. James B. , Engel, Andrew G. , Ensrud, Erik , Ferrante, Mark A., Freimer, Miriam , Gable, Karissa , Gibson, Summer, Gilchrist, James M. , Goldstein, Jonathan , Gooch, Clifton L. , Goodman, Brent P., Gorelov, Dmitri, Gospe, Sídney M. , Goyal, Namita , Guidon, Amanda C. , Guptill, Jeffrey T. , Gutmann, Laurie , Gutmann, Ludwig , Gwathmey, Kelly , Harati, Yadollah, Harper, C. Michel , Hehir, Michael K. , Hobson‐Webb, Lisa D., Howard, James F. , Jackson, Carlayne E. , Jones, Sarah , Juel, Vern C. , Kaminski, Henry J. , Kennelly, Kathleen D., Khella, Sami, Khoury, Julie, Kincaid, John C., Kissel, John T., Kolb, Noah , Lacomis, David , Larriviere, Daniel G., Lewis, Richard A. , Litchy, William J. , Logigian, Eric L. , Lou, Jau-Shin, MacGowen, Daniel J.L., Maselli, Ricardo A. , Massey, Janice M., Mauermann, Michelle L. , Mathews, Katherine D. , Meriggioli, Matthew N. , Moon, Joon-Shik, Mozaffar, Tahseen , Nations, Sharon , Ostrow, Lyle W. , Pascuzzi, Robert M. , Peltier, Amanda , Ruzhansky, Katherine , Ross, Mark A., Rubin, Devon I., Russell, James A., Sachs, George, Salajegheh, Mohammad, Saperstein, David , Scelsa, Stephen N. , Selcen, Duygu , Shaibani, Aziz , Silvestri, Nicholas J. , Singleton, J. Rob, Smith, Benn E., So, Yuen T., Solórzano, Guillermo, Sorenson, Eric J. , Srinivasen, Jayashri, Tavee, Jinny , Tawil, Rabi , Thaisetthawatkul, Pariwat , Thornton, Charles A. , Trivedi, Jaya , Vernino, Steven , Wang, Annabel K., Webb, Tyler A., Weiss, Michael D. , Windebank, Anthony J. , Wolfe, Gil I. , Crum, Brian A. , Dimberg, Elliot, Chahin, Nizar, Cohen, Jeffrey Allen , Johnson, Nicholas E , Karam, Chafic , Ladha, Shafeeq , Li, Yuebing , Miller, Robert G. , Nowak, Richard J. , Richman, David P. , Shieh, Perry B. , Kolb, Noah A , Mauermann, Michelle L , Gutmann, Laurie , Allen, Jeffrey A , Arnold, W David , Vernino, Steven , Kaminski, Henry

Mayo Clinic

Muscle & Nerve | December 13, 2015 | Volume: 53 | Issue: 2 | Pages: 165-168

10.1002/mus.25009 | PMID 26662952 Get It